Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Biochemical screening for congenital defects.

Ray O Bahado-Singh1, Jaime Sutton-Riley

  • 1Department of Obstetrics & Gynecology, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267, USA. bahadoro@ucmail.uc.edu

Obstetrics and Gynecology Clinics of North America
|November 20, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prenatal opioid exposure alters pain perception and increases long-term health risks in infants with neonatal opioid withdrawal syndrome.

Frontiers in pain research (Lausanne, Switzerland)·2025
Same author

Untargeted Metabolomic Biomarker Discovery for the Detection of Ectopic Pregnancy.

International journal of molecular sciences·2024
Same author

Prenatal opioid exposure significantly impacts placental protein kinase C (PKC) and drug transporters, leading to drug resistance and neonatal opioid withdrawal syndrome.

Frontiers in neuroscience·2024
Same author

Metabolomic prediction of severe maternal and newborn complications in preeclampsia.

Metabolomics : Official journal of the Metabolomic Society·2024
Same author

Placental cytochrome P450 methylomes in infants exposed to prenatal opioids: exploring the effects of neonatal opioid withdrawal syndrome on health horizons.

Frontiers in genetics·2024
Same author

The longitudinal biochemical profiling of TBI in a drop weight model of TBI.

Scientific reports·2023

Biochemical screening is standard for estimating pregnancy aneuploidy risk. Combining first and second trimester markers can improve diagnostic accuracy for detecting fetal anomalies.

Area of Science:

  • Biochemistry
  • Prenatal Diagnostics
  • Genetics

Background:

  • Biochemical screening is the established method for assessing the risk of chromosomal abnormalities during pregnancy.
  • Congenital defects pose significant health risks to newborns, necessitating accurate early detection methods.

Purpose of the Study:

  • To review the current state of biochemical screening for congenital defects.
  • To highlight the advancements in combining screening markers for improved diagnostic accuracy.

Main Methods:

  • Review of existing literature on biochemical screening protocols.
  • Analysis of the efficacy of combined first and second trimester screening markers.

Main Results:

  • Biochemical screening continues to be the gold standard for aneuploidy risk assessment.

Related Experiment Videos

  • The integration of markers from both the first and second trimesters shows potential for enhanced anomaly detection.

    • Conclusions:

    • Biochemical screening plays a crucial role in prenatal diagnostics.
    • Future improvements in diagnostic accuracy for congenital defects can be achieved through combined screening marker strategies.